• Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results

    Source: Nasdaq GlobeNewswire / 23 Feb 2022 15:01:00   America/Chicago

    IRVINE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2021.

    Fourth Quarter Revenue and Business Highlights:

    • Treated 7,700 patients, an increase of 15% over the third quarter. Over 90% of overall procedures and sequential procedural growth came from non-COVID patients.
    • Generated revenue of $83.2 million in the fourth quarter of 2021, up 14% sequentially and 71% over the same quarter last year, and finished full year 2021 with revenue of $277 million, a 98% increase over full year 2020.
    • Enrolled the first patient into our PEERLESS randomized controlled trial in PE, enrolled the 800th and final patient into the U.S. arm of the FLASH PE registry and enrolled the 500th and final patient into the CLOUT DVT registry.
    • Ended 2021 with over 200 U.S. sales territories.
    • Ended the quarter with $180.1 million in cash, cash equivalents and investments.

    “Our fourth quarter was again successful and productive. We treated 1,000 more patients than in the third quarter and made significant progress on all of our growth drivers,” said Bill Hoffman CEO of Inari Medical. “We are especially pleased with the milestones we achieved on several clinical studies. Most notably, we enrolled our first patient into our PEERLESS randomized controlled trial. In addition, we completed enrollment in both the CLOUT registry and the U.S. arm of our FLASH registry, the largest prospective thrombectomy trials ever conducted in DVT and PE. We love every second of this work and we remain thankful for the opportunity to serve our patients and our mission.”

    Fourth Quarter 2021 Financial Results
    Revenue was $83.2 million for the fourth quarter of 2021, compared to $72.9 million for the prior quarter and $48.6 million for the fourth quarter of 2020. The increase over prior quarter was driven by continued U.S. commercial expansion and new product introductions.

    Gross profit was $74.9 million for the fourth quarter of 2021, compared to $44.9 million for the same period of 2020. Gross margin was 90.1% for the fourth quarter of 2021, compared to 92.4% for the same period in the prior year, modestly lower primarily due to the move to our larger production facility in the fourth quarter of 2021.

    Operating expenses for the fourth quarter of 2021 were $73.2 million, compared to $37.9 million for the fourth quarter of 2020. The increase was mainly driven by an increase in personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, and clinical and support organizations.

    Net income was $1.1 million for the fourth quarter of 2021 and net income per share was $0.02 on a weighted-average basic share count of 50.2 million and $0.02 on a weighted average diluted share count of 55.6 million, compared to a net income of $7.0 million and a net income per share of $0.14 and $0.13 on a weighted-average basic share count of 48.7 million and diluted share count of 55.2 million, respectively, in the same period of the prior year.

    Full Year 2021 Financial Results
    Revenue was $277.0 million for the year ended December 31, 2021, compared to $139.7 million in the prior year. The increase over prior year was driven by our continued U.S. commercial expansion and new product introductions.

    Gross profit was $252.2 million for the full year of 2021, compared to $126.6 million for the same period of 2020. Gross margin increased slightly to 91.1% for the full year of 2021, compared to 90.6% for the prior year.

    Operating expenses for the full year of 2021 were $241.4 million, compared to $108.1 million for the full year 2020.

    Net income was $9.8 million for the full year of 2021 and net income per share was $0.20 and 0.18 on a weighted-average basic share count of 49.8 million and 55.6 million, respectively, compared to a net income of $13.8 million and net income per share of $0.43 and $0.27 on a weighted-average basic share count of 32.0 million and diluted share count of 51.6 million, respectively, in the prior year.

    Full-Year 2022 Revenue Guidance
    Inari Medical is providing financial guidance as follows:

    For the full year 2022, revenue of $350 million to $360 million, reflecting growth of approximately 26% to 30% over 2021.

    Webcast and Conference Call Information
    Inari Medical will host a conference call to discuss the fourth quarter and full year 2021 financial results after market close on Wednesday, February 23, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 519-1265 for U.S. callers or (914) 800-3838 for international callers, using conference ID: 3126888. The live webinar can be accessed at https://ir.inarimedical.com.

    About Inari Medical, Inc.
    Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

    Forward Looking Statements
    Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2022 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

    Investor Contact:
    ICR Westwicke
    Caroline Corner
    Phone +1-415-202-5678
    caroline.corner@westwicke.com 

     
    INARI MEDICAL, INC.
    Consolidated Statements of Operations and Comprehensive Income (Loss)
    (in thousands, except share and per share data)
    (unaudited)
             
      Three Months Ended December 31, Years Ended December 31,
       2021   2020   2021   2020 
    Revenue $83,218  $48,610  $276,984  $139,670 
    Cost of goods sold  8,280   3,685   24,757   13,106 
    Gross profit  74,938   44,925   252,227   126,564 
    Operating expenses        
    Research and development  18,726   6,536   51,018   18,399 
    Selling, general and administrative  54,466   31,393   190,365   89,746 
    Total operating expenses  73,192   37,929   241,383   108,145 
    Income from operations  1,746   6,996   10,844   18,419 
    Other income (expense)    0     
    Interest income  24   75   154   484 
    Interest expense  (75)  (75)  (295)  (1,135)
    Change in fair value of warrant liabilities           (3,317)
    Other expense, net  (14)  (11)  (18)  (662)
    Total other expenses  (65)  (11)  (159)  (4,630)
    Income before income taxes  1,681   6,985   10,685   13,789 
    Provision for income taxes  574      845    
    Net income $1,107  $6,985  $9,840  $13,789 
    Other comprehensive income (loss)        
    Foreign currency translation adjustments  (110)     (379)   
    Unrealized (loss) gain on available-for-sale securities  (46)  4   (27)  4 
    Total other comprehensive income (loss)  (156)  4   (406)  4 
    Comprehensive income $951  $6,989  $9,434  $13,793 
    Net income per share   $-     
    Basic $0.02  $0.14  $0.20  $0.43 
    Diluted $0.02  $0.13  $0.18  $0.27 
    Weighted average common shares used to        
    compute net income per share        
    Basic  50,229,356   48,742,302   49,815,914   32,033,827 
    Diluted  55,627,807   55,221,012   55,594,159   51,554,996 
             


    INARI MEDICAL, INC.
    Consolidated Balance Sheets
    (in thousands, except share data and par value)
    (unaudited)
         
      December 31,
       2021   2020 
    Assets    
    Current assets    
    Cash and cash equivalents $92,752  $114,229 
    Short-term investments  83,348   49,981 
    Accounts receivable, net  42,351   28,008 
    Inventories, net  21,053   10,597 
    Prepaid expenses and other current assets  5,694   2,808 
    Restricted cash     50 
    Total current assets  245,198   205,673 
    Property and equipment, net  16,471   7,498 
    Operating lease right-of-use assets  44,909    
    Long-term investments  3,983    
    Deposits and other assets  981   583 
    Restricted cash     338 
    Total assets $311,542  $214,092 
    Liabilities and Stockholders' Equity    
    Current liabilities    
    Accounts payable $6,541  $3,047 
    Payroll-related accruals  24,433   8,198 
    Accrued expenses and other current liabilities  10,737   2,593 
    Operating lease liabilities, current portion  802    
    Total current liabilities  42,513   13,838 
    Operating lease liabilities, noncurrent portion  28,404    
    Other long-term liability  1,416    
    Total liabilities  72,333   13,838 
         
    Commitments and contingencies (Note 7)    
         
    Stockholders' equity    
    Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares         
    issued and outstanding as of December 31, 2021 and December 31, 2020      
    Common stock, $0.001 par value, 300,000,000 shares authorized         
    as of December 31, 2021 and December 31, 2020;
    50,313,452 and 49,251,614 shares issued and outstanding
    as of December 31, 2021 and December 31, 2020, respectively
      50   49 
    Additional paid in capital  257,144   227,624 
    Accumulated other comprehensive (loss) income  (402)  4 
    Accumulated deficit  (17,583)  (27,423)
    Total stockholders' equity   239,209   200,254 
    Total liabilities and stockholders' equity  $311,542  $214,092 
         

     


    Primary Logo

Share on,